FTC to appeal antitrust ruling on GRAIL acquisition
RiverNorthPhotography


The Federal Trade Commission intends to appeal an administrative law judgeâs ruling that the acquisition of cancer test developer GRAIL by Illumina (NASDAQ:ILMN) would not undermine competition, Reuters reported Friday, citing the agency.
FTC Director of the Bureau of Competition Holly Vedova had also said on Thursday the agency might challenge the ruling in which the judge rejected the regulatorâs position that the $7.1B deal will not hurt competition in the market for multicancer early detection tests.

In 2021, the company declared the completion of the GRAIL acquisition despite ongoing regulatory challenges in the U.S. and Europe. The European Commission is expected to issue its decision on the ILMN-GRAIL antitrust case by Sep. 12.
Seeking Alpha contributor William Meyers argues that the concessions ILMN will have to offer to win over EU officials can âtake away much of Grailâs advantage over rivals.â